Studies

263 studies · Download as JSON

• Effects of GLP-1 Receptor Agonists and Dual GIP/GLP-1 Receptor Agonists on Inflammatory and Metabolic Biomarkers in Type 2 Diabetes: A Systematic Review and Meta-AnalysisMeta-analysis · 2026 · Study tier 3 · Different population · Benefit
• Effects of semaglutide and empagliflozin on markers of endothelial function in persons with type 2 diabetes: A post hoc analysis of a randomized clinical trialRandomized trial · 2026 · Study tier 3 · Different population · Mixed · Unreviewed automatic assessment
• A Systematic Review and Meta-Analysis of Malnutrition and Metabolic Failure in High-Potency Incretin TherapyMeta-analysis · 2026 · Study tier 2 · Different population · Unclear · Unreviewed automatic assessment
• Patient-Reported Continuity of GLP-1 Receptor Agonist TherapyRetrospective cohort · 2026 · Study tier 3 · Different population · Harm direction · Unreviewed automatic assessment
• Comparative Efficacy of Tirzepatide Versus Semaglutide for Weight Loss in Adults With Overweight or Obesity: A Systematic Review and Meta-Analysis of Head-to-Head StudiesMeta-analysis · 2026 · Study tier 2 · Different population · Mixed · Unreviewed automatic assessment
• Oral semaglutide for weight loss and liver fibrosis in overweight and obesity: A randomized controlled trialRandomized trial · 2026 · Study tier 3 · Different population · Benefit · Unreviewed automatic assessment
• GLP-1 receptor agonist use and mental health outcomes in adolescents with obesity: a retrospective reviewCase-control · 2026 · Study tier 4 · Different population · Null · Unreviewed automatic assessment
• GLP-1 Receptor Agonists and Musculoskeletal Outcomes: A Systematic Literature Review and Meta-AnalysisMeta-analysis · 2026 · Study tier 2 · Different population · Unclear · Unreviewed automatic assessment
• Metabolic Effects of a GLP-1 Analog Combined with Aerobic Training in Ovariectomized RatsAnimal study · 2026 · Study tier 4 · Not human evidence · Harm direction · Unreviewed automatic assessment
• Glucagon-like peptide-1 receptor activation, inflammation and heart failure: Insights from genetic analysisMendelian randomization · 2026 · Study tier 3 · Population unclear · Unclear · Unreviewed automatic assessment
• Postoperative outcomes after total knee arthroplasty in type 2 diabetes mellitus patients receiving semaglutide versus tirzepatide: a propensity score-matched national research network analysisRetrospective cohort · 2026 · Study tier 3 · Different population · Unclear · Unreviewed automatic assessment
• Preoperative GLP-1 receptor agonist use and outcomes after total hip arthroplasty: a matched cohort studyRetrospective cohort · 2026 · Study tier 3 · Population unclear · Harm direction · Unreviewed automatic assessment
• Assessing the Association Between GLP-1 Receptor Agonists and Diabetic Foot Complications Using Real-World Pharmacovigilance Database and Mendelian RandomizationMendelian randomization · 2026 · Study tier 3 · Population unclear · Harm direction · Unreviewed automatic assessment
• Comparative outcomes for tirzepatide versus glucagon-like peptide-1 receptor agonists in patients with inflammatory bowel disease: a national propensity matched studyRetrospective cohort · 2026 · Study tier 3 · Population unclear · Benefit · Unreviewed automatic assessment
• Carbon Emission Impact of Semaglutide in People with Obesity in the UK Using a Disease Modelling ApproachRetrospective cohort · 2026 · Study tier 3 · Different population · Benefit · Unreviewed automatic assessment
• Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists as Adjuncts to Insulin Therapy in Type 1 Diabetes Mellitus: An Overlap-Informed Umbrella ReviewUmbrella review · 2026 · Study tier 2 · Population unclear · Mixed · Unreviewed automatic assessment
• A Comparison of Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors in Reducing the Incidence of Tuberculosis and Mortality in Patients with DiabetesRetrospective cohort · 2026 · Preliminary · Population unclear · Mixed · Not peer reviewed · Unreviewed automatic assessment
• Tirzepatide and the Incidence of Atrial Fibrillation in Adults With Overweight or Obesity: An Updated Meta-Analysis of Randomized Controlled TrialsMeta-analysis · 2026 · Study tier 2 · Different population · Null · Unreviewed automatic assessment
• A retrospective cohort study on the comparative safety of glucagon-like peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors on the onset of gallbladder disease in type II diabetesRetrospective cohort · 2026 · Study tier 3 · Population unclear · Unclear · Unreviewed automatic assessment
• Association of GLP-1 Receptor Agonists Versus Other Antidiabetic Medications With Cardiovascular, Renal, and Liver Outcomes in Patients With Type 2 DiabetesRetrospective cohort · 2026 · Study tier 3 · Different population · Benefit · Unreviewed automatic assessment
• Finerenone-Based Dual Versus Triple Therapy with SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes Mellitus Associated Chronic Kidney Disease: A Retrospective Cohort StudyRetrospective cohort · 2026 · Study tier 3 · Different population · Null · Unreviewed automatic assessment
• Vagal activity related events and glucagon-like peptide-1 receptor agonistsRetrospective cohort · 2026 · Study tier 3 · Different population · Null · Unreviewed automatic assessment
• Delayed gastric emptying in adolescent patients on GLP-1 receptor agonists with standard preoperative fasting guidelines: a prospective cohort studyProspective cohort · 2026 · Study tier 3 · Different population · Unclear · Unreviewed automatic assessment
• Education and Alzheimer Disease Genetic Risk in Associations of GLP-1 Receptor Agonists With Dementia Among Adults With Type 2 DiabetesRetrospective cohort · 2026 · Preliminary · Different population · Unclear · Not peer reviewed · Unreviewed automatic assessment
• Semaglutide and Papillary Thyroid Carcinoma: Current Evidence on Risk, Progression, and MechanismsPharmacovigilance · 2026 · Preliminary · Different population · Null · Not peer reviewed · Unreviewed automatic assessment
• Impact of GLP-1 Dose Intensity on Perioperative and Long-Term Fusion Outcomes Following ACDFRetrospective cohort · 2026 · Study tier 3 · Different population · Null · Unreviewed automatic assessment
• GLP-1 receptor agonists vs DPP-4 inhibitors and neuropathic complications in type 2 diabetesRetrospective cohort · 2026 · Study tier 3 · Different population · Benefit · Unreviewed automatic assessment
• The impact of glucagon-like peptide-1 (GLP-1) receptor agonists on postoperative outcomes following rotator cuff repairRetrospective cohort · 2026 · Study tier 3 · Population unclear · Null · Unreviewed automatic assessment
• Sodium-Glucose Cotransporter-2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, and Incident Atrial Fibrillation in Type 2 Diabetes: A Population-Based Target Trial EmulationRetrospective cohort · 2026 · Study tier 3 · Different population · Benefit · Unreviewed automatic assessment
• HIF-1 plays a dual regulatory role in hippocampal neuronal PANoptosis in Alzheimer's disease via the HK2/VDAC1/NLRP3 axis and RIPK3 signalingAnimal study · 2026 · Study tier 4 · Not human evidence · Benefit · Unreviewed automatic assessment
• GLP-1 receptor agonist use is associated with shorter survival in patients with amyotrophic lateral sclerosis and diabetes mellitusRetrospective cohort · 2026 · Preliminary · Different population · Harm direction · Not peer reviewed · Unreviewed automatic assessment
• Safety and Glycemic Efficacy of Perioperative Liraglutide in Cardiac Surgery: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsMeta-analysis · 2026 · Study tier 2 · Population unclear · Null · Unreviewed automatic assessment
• Liraglutide Attenuates Hepatocyte Ferroptosis in an In Vitro Model of Metabolic Dysfunction-Associated Steatotic Liver DiseaseCell / in-vitro · 2026 · Study tier 4 · Not human evidence · Benefit · Unreviewed automatic assessment
• Tirzepatide preserves hematopoietic stem and progenitor cycling while remodeling inflammatory monocytes in obese miceAnimal study · 2026 · Preliminary · Not human evidence · Unclear · Not peer reviewed · Unreviewed automatic assessment
• Postmarketing Safety Signals and Medication-Use Risks of GLP-1-Based Therapies in Diabetes and Obesity: A Multi-Source Pharmacovigilance and Regulatory Evidence-Mapping StudyPharmacovigilance · 2026 · Study tier 4 · Different population · Harm direction · Unreviewed automatic assessment
• GLP1-RA Use and Risk of Non-arteritic Anterior Ischemic Optic Neuropathy in Patients with Type 2 DiabetesRetrospective cohort · 2026 · Study tier 3 · Different population · Harm direction · Unreviewed automatic assessment
• Use of Glucose-Lowering Drugs for Type 2 Diabetes Among Danish Care Home ResidentsRetrospective cohort · 2026 · Study tier 3 · Population unclear · Unclear · Partly industry funded · Unreviewed automatic assessment
• Glucagon-like Peptide-1 Receptor Agonist-Associated Injection Site and Dermatologic ReactionsPharmacovigilance · 2026 · Study tier 4 · Different population · Harm direction · Unreviewed automatic assessment
• What is the association between insulin dependence and the incidence of postoperative complications, perioperative glucose control, and five-year reoperation rates after total joint replacement?Retrospective cohort · 2026 · Study tier 3 · Population unclear · Unclear · Unreviewed automatic assessment
• The GLP-1 Nutritional Paradox: A Global Meta-Analysis of Sarcopenic Risks and Micronutrient Gaps in the Post-Obesity EraMeta-analysis · 2026 · Preliminary · Different population · Harm direction · Not peer reviewed · Unreviewed automatic assessment
• Real-World EHR Signals from a Cohort of Blinded Incretin Trial Participants Motivate Novel Indication OpportunitiesRetrospective cohort · 2026 · Preliminary · Different population · Null · Not peer reviewed · Unreviewed automatic assessment
• Microbiome and Metabolomics in Obesity: Advances in Understanding and Interventions Across the LifespanProspective cohort · 2026 · Study tier 3 · Different population · Mixed · Unreviewed automatic assessment
• Integrating the liver into the cardiovascular-kidney-metabolic syndrome: pathophysiology and therapeutic implicationsRetrospective cohort · 2026 · Study tier 3 · Different population · Unclear · Unreviewed automatic assessment
• Cardiometabolic outcomes of once-weekly IcoSema in adults with type 2 diabetes: systematic review and meta-analysis of the COMBINE trialsMeta-analysis · 2026 · Study tier 2 · Different population · Benefit · Unreviewed automatic assessment
• Comparative Short-term Risk of Severe Gastrointestinal Events Associated With Opioid Type Among Patients Receiving Glucagon-Like Peptide-1 Receptor AgonistsRetrospective cohort · 2026 · Study tier 3 · Different population · Unclear · Unreviewed automatic assessment
• Multi-Database Pharmacovigilance Analysis of Gastroesophageal Reflux Disease Associated with GLP-1 Receptor Agonists: A Cross-National Signal Validation StudyPharmacovigilance · 2026 · Study tier 4 · Different population · Harm direction · Unreviewed automatic assessment
• Glucagon-like Peptide-1 Receptor Agonist Use and Risk of Postmastectomy Lymphedema in Breast Cancer Survivors: A Multicenter Real-World Cohort StudyRetrospective cohort · 2026 · Preliminary · Different population · Unclear · Not peer reviewed · Unreviewed automatic assessment
• GLP-1/GIP Uptake, Indication, and Access Pathways Among US Adults in the Understanding America StudyProspective cohort · 2026 · Preliminary · Different population · Harm direction · Not peer reviewed · Unreviewed automatic assessment
• Effect of Combination Therapy with SGLT2 Inhibitors and GLP-1 Receptor Agonists on Myocardial Infarction and Stroke in Type 2 Diabetes: A Systematic Review and Meta-AnalysisMeta-analysis · 2026 · Study tier 3 · Different population · Benefit · Unreviewed automatic assessment
• Investigating the Relationship Between Glucagon-Like Peptide-1 Receptor Agonist Use and Incidence of Vertebral Fractures in Female Patients Aged Over 50 Years With Osteoporosis: A Propensity-Matched AnalysisRetrospective cohort · 2026 · Study tier 3 · Different population · Benefit · Unreviewed automatic assessment
• Genetic and Clinical Determinants of Variation in Drug Response in Type 2 Diabetes: Insights From the Scottish and UK Biobank CohortsRetrospective cohort · 2026 · Study tier 3 · Different population · Unclear · Partly industry funded · Unreviewed automatic assessment
• Higher semaglutide dose is associated with lower neuropsychiatric event incidence independent of weight lossRetrospective cohort · 2026 · Study tier 3 · Different population · Benefit · Unreviewed automatic assessment
• Clinical Evidence of Skin Improvements With a Biologically Active Multimodal Topical Skin TreatmentClinical trial · 2026 · Study tier 4 · Population unclear · Unclear · Unreviewed automatic assessment
• Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes : An Updated Systematic ReviewSystematic review · 2026 · Study tier 2 · Different population · Unclear · Unreviewed automatic assessment
• Cardiorenal Protection in Type 2 Diabetes: A Systematic Review Comparing Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 InhibitorsSystematic review · 2026 · Study tier 2 · Different population · Mixed · Unreviewed automatic assessment
• Efficacy and Safety of Tirzepatide Versus Dulaglutide in Type 2 Diabetes With or Without Established Atherosclerotic Cardiovascular Disease: A Network Meta-Analysis of Randomized Clinical TrialsMeta-analysis · 2026 · Study tier 2 · Different population · Unclear · Unreviewed automatic assessment
• Comparative effectiveness of GLP-1 receptor agonists versus mineralocorticoid receptor antagonists as fourth-line pharmacological therapy in patients with resistant hypertension and overweight or obesity: a retrospective multicenter cohort study in the USARetrospective cohort · 2026 · Study tier 3 · Different population · Unclear · Unreviewed automatic assessment
• Comparative Cardiovascular Outcomes of GLP-1 Receptor Agonists Versus Bariatric Surgery: A Systematic Review and Network Meta-AnalysisMeta-analysis · 2026 · Study tier 3 · Different population · Unclear · Unreviewed automatic assessment
• Effects of Glucagon-Like Peptide-1 Receptor Agonist Use After Transient Ischemic Attack on Risks of Subsequent Ischemic Stroke and MortalityRetrospective cohort · 2026 · Study tier 3 · Population unclear · Benefit · Unreviewed automatic assessment
• Late-life semaglutide treatment slows ageing and extends lifespan in female miceAnimal study · 2026 · Study tier 4 · Not human evidence · Mixed · Unreviewed automatic assessment
• Weight Regain Trajectories After Discontinuation of Semaglutide or Tirzepatide: A Reconstructed Aggregate-Data Bayesian Longitudinal Meta-AnalysisMeta-analysis · 2026 · Study tier 3 · Population unclear · Unclear · Unreviewed automatic assessment
• Sex in CKD trials: representation and treatment effects of cardiorenoprotective therapiesRetrospective cohort · 2026 · Study tier 3 · Different population · Mixed · Unreviewed automatic assessment
• Association of tirzepatide with changes in OSA-related measures based on baseline characteristics - post hoc analyses of SURMOUNT-OSARandomized trial · 2026 · Study tier 3 · Different population · Benefit · Unreviewed automatic assessment
• Combined GLP-1 Receptor Agonist and SGLT2 Inhibitor Therapy for Adults with Type 2 Diabetes and Chronic Obstructive Pulmonary Disease: A Large-Scale Target Trial EmulationRetrospective cohort · 2026 · Preliminary · Different population · Mixed · Not peer reviewed · Unreviewed automatic assessment
• GLP-1 Receptor Agonist Initiation and Anti-VEGF Treatment Frequency in Diabetic Macular Edema: an IRIS ^® Registry Cohort StudyRetrospective cohort · 2026 · Preliminary · Different population · Null · Not peer reviewed · Unreviewed automatic assessment
• Assessing Type 2 Diabetes and GLP-1 agonist response trajectories with a proteogenomic atlas of disease progressionMendelian randomization · 2026 · Preliminary · Population unclear · Unclear · Not peer reviewed · Unreviewed automatic assessment
• Intrathecal semaglutide attenuates burn injury-induced pain in mice through a spinal GLP-1R-linked enkephalin/δ-opioid receptor pathwayAnimal study · 2026 · Study tier 4 · Not human evidence · Harm direction · Unreviewed automatic assessment
• Effects of subcutaneous semaglutide on weight loss and inflammatory markers in adults with overweight or obesity without diabetes: a systematic review and meta-analysisMeta-analysis · 2026 · Study tier 2 · Different population · Unclear · Unreviewed automatic assessment
• Comparative Efficacy of Promising Targets in the Treatment of Metabolic Dysfunction-associated Steatotic Liver Disease and Steatohepatitis: A Systematic Review and Network Meta-analysisMeta-analysis · 2026 · Study tier 2 · Population unclear · Benefit · Unreviewed automatic assessment
• FDA prescribing information: Zepbound, ZEPBOUND (TIRZEPATIDE) - label effective 2026-08-28Regulatory document · 2026 · Not rated · Population unclear · Harm direction · Not peer reviewed · Unreviewed automatic assessment
• Effect of Semaglutide on the Inflammatory Biomarker High-Sensitivity CRP in Patients With Established Cardiovascular Disease and Overweight or Obesity in SELECT: A Prespecified Secondary AnalysisPrespecified secondary (sub-study) analysis of a randomized, double-blind, placebo-controlled, parallel-group phase 3 trial (select) · 2026 · Study tier 2 · Different population · Benefit · Industry funded
• Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 DiabetesRandomized trial · 2026 · Study tier 3 · Different population · Unclear · Industry funded · Unreviewed automatic assessment
• Comprehensive Long-Term Changes in Cardiovascular Risk Biomarkers With Tirzepatide: A SURMOUNT-1 Post Hoc AnalysisRandomized trial · 2026 · Study tier 3 · Different population · Benefit · Unreviewed automatic assessment
• Treatment strategies for functional hypogonadism in obese men: a systematic review and network meta-analysisMeta-analysis · 2026 · Study tier 2 · Different population · Mixed · Unreviewed automatic assessment
• The GLP-1-Mitochondria Axis in Metabolic AgingMechanistic review · 2026 · Not rated · Not human evidence · Unclear
• Comparative Efficacy and Safety of Tirzepatide Versus Semaglutide for Obesity: A Systematic ReviewSystematic review · 2026 · Study tier 2 · Different population · Mixed · Unreviewed automatic assessment
• Diabetes, Adiposity, and Functional Phenotypes in HFpEF: A Systematic Review of Recent Treatment-Response EvidenceSystematic review · 2026 · Study tier 2 · Different population · Benefit · Unreviewed automatic assessment
• Neuropsychiatric Effects of Glucagon-Like Peptide-1 Receptor Agonists in Schizophrenia-Spectrum Disorders: A Systematic ReviewSystematic review · 2026 · Study tier 2 · Population unclear · Mixed · Unreviewed automatic assessment
• Incretin-Based Therapies Versus Bariatric and Metabolic Surgery for Obesity and Type 2 Diabetes Mellitus: A Head-to-Head Systematic Review of Glycaemic, Cardiovascular, Hepatic, Weight, and Quality-of-Life OutcomesSystematic review · 2026 · Study tier 2 · Different population · Mixed · Unreviewed automatic assessment
• Suspected Biphasic Anaphylaxis Following the First Known Dose of Tirzepatide: A Case Report and Brief Review of Reported Hypersensitivity ReactionsPharmacovigilance · 2026 · Study tier 4 · Population unclear · Null · Unreviewed automatic assessment
• Short-Term Combined Treatment With Tirzepatide and Metformin for Overweight/Obese Chinese Women With Polycystic Ovary Syndrome: A Prospective, Open-Label, Randomised Controlled TrialRandomized trial · 2026 · Study tier 3 · Different population · Benefit · Unreviewed automatic assessment
• Tirzepatide therapy reduces subclinical leaflet thrombosis and paravalvular leak after transcatheter aortic valve replacement in obese patients: The TAVR-MET trialRandomized trial · 2026 · Study tier 3 · Different population · Mixed · Unreviewed automatic assessment
• Cardiovascular outcome of glucagon-like peptide-1 receptor agonists vs dipeptidyl peptidase-4 inhibitor on end-stage kidney disease patients with heart failure: an emulated target trial in patients with diabetesRetrospective cohort · 2026 · Study tier 3 · Population unclear · Benefit · Unreviewed automatic assessment
• FDA prescribing information: Ozempic (SEMAGLUTIDE) - label effective 2026-07-30Regulatory document · 2026 · Not rated · Population unclear · Null · Not peer reviewed · Unreviewed automatic assessment
• FDA prescribing information: MOUNJARO (TIRZEPATIDE) - label effective 2026-07-29Regulatory document · 2026 · Not rated · Population unclear · Harm direction · Not peer reviewed · Unreviewed automatic assessment
• FDA prescribing information: Liraglutide (LIRAGLUTIDE) - label effective 2026-07-27Regulatory document · 2026 · Not rated · Population unclear · Null · Not peer reviewed · Unreviewed automatic assessment
• Cardiovascular Outcomes of GLP-1-Based Medicines Among People With Overweight and Obesity: An Umbrella Review of Meta-Analyses of Randomized Controlled TrialsUmbrella review · 2026 · Study tier 2 · Different population · Mixed
• Prevention of Vascular Aging as a Novel Paradigm for GLP-1 Receptor Agonist-Mediated CardioprotectionMechanistic review · 2026 · Not rated · Not human evidence · Unclear
• Effects of Tirzepatide in Obesity-Related HFpEF by Sex: A Prespecified Secondary Analysis From the SUMMIT TrialRandomized trial · 2026 · Study tier 2 · Different population · Mixed · Unreviewed automatic assessment
• Effects of Semaglutide on Body Composition and GFR: A Prespecified Analysis of the SMART TrialRandomized trial · 2026 · Study tier 3 · Different population · Mixed · Industry funded
• Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trialRandomized trial · 2026 · Study tier 3 · Different population · Mixed · Industry funded
• Autoimmune Disease Risk With GLP-1RA, DPP-4i, and SGLT2i Treatment in Patients With DiabetesRetrospective cohort · 2026 · Study tier 4 · Different population · Mixed
• Effects of exercise and liraglutide on vascular health and inflammation during weight loss maintenance: a prespecified secondary analysis of the S-LiTE trialRandomized trial · 2026 · Study tier 3 · Different population · Benefit · Partly industry funded · Unreviewed automatic assessment
• Short-term comparative effects of semaglutide, either alone or in conjunction with canagliflozin, on early diabetic kidney diseaseRandomized trial · 2026 · Study tier 3 · Population unclear · Benefit · Unreviewed automatic assessment
• FDA prescribing information: Trulicity (DULAGLUTIDE) - label effective 2026-06-16Regulatory document · 2026 · Not rated · Population unclear · Null · Not peer reviewed · Unreviewed automatic assessment
• Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trialRandomized trial · 2026 · Study tier 2 · Different population · Benefit · Industry funded
• Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trialsRandomized trial · 2026 · Study tier 1 · Partial match · Null · Industry funded
• FDA prescribing information: Exenatide (EXENATIDE) - label effective 2026-05-27Regulatory document · 2026 · Not rated · Population unclear · Mixed · Not peer reviewed · Unreviewed automatic assessment
• Effects of Semaglutide on Cognitive Function in People With HIV: A Randomized, Controlled TrialRandomized trial · 2026 · Study tier 3 · Population unclear · Unclear · Unreviewed automatic assessment
• Efficacy and safety of GLP-1 receptor agonists in Parkinson's disease: a systematic review and meta-analysis of randomized clinical trialsMeta-analysis · 2026 · Study tier 2 · Partial match · Null
• Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes: A Post Hoc Secondary Analysis of the SOUL Randomized Clinical TrialRandomized trial · 2026 · Study tier 1 · Different population · Benefit · Unreviewed automatic assessment
• Semaglutide-associated risk of nonarteritic anterior ischemic optic neuropathy in patients with type 2 diabetes: A systematic review and meta-analysis of observational studiesMeta-analysis · 2026 · Study tier 3 · Different population · Harm direction
• Incretin-Based Therapies in Obesity-Related Heart Failure With Preserved Ejection Fraction (HFpEF): A Systematic Review of Emerging Cardiometabolic Disease Modification Beyond Glycemic ControlSystematic review · 2026 · Study tier 2 · Different population · Mixed · Unreviewed automatic assessment
• Tirzepatide Beyond Diabetes and Obesity: Systematic Review and Meta-Analysis of Multisystem Therapeutic BenefitsMeta-analysis · 2026 · Study tier 2 · Different population · Benefit · Unreviewed automatic assessment
• FDA prescribing information: Soliqua 100/33 (INSULIN GLARGINE AND LIXISENATIDE) - label effective 2026-03-18Regulatory document · 2026 · Not rated · Population unclear · Harm direction · Not peer reviewed · Unreviewed automatic assessment
• Tirzepatide on obstructive sleep apnea-related cardiometabolic risk: secondary outcomes of the SURMOUNT-OSA randomized trialRandomized trial · 2026 · Study tier 3 · Different population · Benefit · Unreviewed automatic assessment
• FDA prescribing information: OZEMPIC, RYBELSUS (ORAL SEMAGLUTIDE) - label effective 2026-01-30Regulatory document · 2026 · Not rated · Population unclear · Harm direction · Not peer reviewed · Unreviewed automatic assessment
• FDA prescribing information: Liraglutide (LIRAGLUTIDE) - label effective 2026-01-30Regulatory document · 2026 · Not rated · Population unclear · Null · Not peer reviewed · Unreviewed automatic assessment
• Liraglutide in mild to moderate Alzheimer's disease: a phase 2b clinical trialRandomized trial · 2026 · Study tier 3 · Partial match · Mixed · Partly industry funded
• Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trialsTrial registration · 2026 · Preliminary · Different population · Unclear · Industry funded
• Long-Term Cardiovascular Outcomes of Glucagon-Like Peptide-1 Receptor Agonists in Non-diabetic Obesity: A Systematic Review and Meta-AnalysisMeta-analysis · 2026 · Study tier 2 · Different population · Mixed · Unreviewed automatic assessment
• Effect of Glucagon-Like Peptide-1 Receptor Agonists on Cardiometabolic Risk Factors in Type 1 Diabetes Mellitus: A Systematic Review and Meta-AnalysisMeta-analysis · 2026 · Study tier 2 · Population unclear · Benefit · Unreviewed automatic assessment
• Tirzepatide and the risk of asthma exacerbations in patients with type 2 diabetesRetrospective cohort · 2026 · Study tier 3 · Different population · Benefit · Unreviewed automatic assessment
• Prehospital glucagon-like peptide-1 receptor agonists are not associated with reduced inpatient opioid exposure but with shorter hospital length of stay after total joint arthroplastyRetrospective cohort · 2026 · Study tier 3 · Population unclear · Mixed · Unreviewed automatic assessment
• Weight regain following discontinuation of glucagon-like peptide-1 receptor agonists in adults who are overweight or obese: a systematic review and meta-analysisMeta-analysis · 2026 · Study tier 2 · Different population · Harm direction · Unreviewed automatic assessment
• Effects of GLP-1 receptor agonists on the incidence of contrast-induced acute kidney injury in patients with Type 2 diabetes mellitus undergoing coronary interventionsRetrospective cohort · 2026 · Study tier 3 · Different population · Benefit · Unreviewed automatic assessment
• Associations Between Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) and Cancer Risk: A Systematic Review and Meta-AnalysisMeta-analysis · 2026 · Study tier 3 · Different population · Benefit · Unreviewed automatic assessment
• Efficacy of SGLT2 inhibitors, GLP-1 receptor agonists, and aerobic exercise for moderate-to-severe obstructive sleep apnea in overweight or obese patients: a network meta-analysisMeta-analysis · 2026 · Study tier 2 · Different population · Benefit · Unreviewed automatic assessment
• Low baseline HbA1c and reduced eGFR are associated with relatively unfavorable body recomposition after SGLT2 inhibitor therapy in type 2 diabetesRetrospective cohort · 2026 · Study tier 3 · Different population · Harm direction · Unreviewed automatic assessment
• Impact of GLP-1 receptor agonists on patients with intraductal papillary mucinous neoplasms: Study protocol for a multicentric cohort studyRetrospective cohort · 2026 · Study tier 3 · Different population · Benefit · Unreviewed automatic assessment
• Reporting patterns of suicide- and self-injury-related events involving liraglutide, semaglutide, and tirzepatide: data from the European pharmacovigilance databasePharmacovigilance · 2026 · Study tier 4 · Different population · Harm direction · Unreviewed automatic assessment
• Use of incretin receptor agonists in patients submitted to metabolic bariatric surgery - a systematic review and meta-analysisMeta-analysis · 2026 · Study tier 3 · Population unclear · Harm direction · Unreviewed automatic assessment
• Comparative efficacy and safety of glucagon-like peptide 1 based drugs for weight loss in adults with overweight or obesity without diabetes: network meta-analysis of randomised controlled trialsMeta-analysis · 2026 · Study tier 2 · Different population · Unclear · Unreviewed automatic assessment
• Association of Tirzepatide versus Semaglutide with Risk of Asthma Exacerbation in Patients with Asthma and Type 2 Diabetes: A US Multicenter Retrospective Cohort StudyRetrospective cohort · 2026 · Study tier 3 · Population unclear · Null · Unreviewed automatic assessment
• The effects of GLP-1 receptor agonists on metabolic inflammatory markers in patients with type 2 diabetes mellitus: a systematic review and meta-analysisMeta-analysis · 2026 · Study tier 3 · Different population · Unclear · Unreviewed automatic assessment
• Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 DiabetesRandomized trial · 2025 · Study tier 1 · Different population · Mixed · Industry funded
• FDA prescribing information: Liraglutide (LIRAGLUTIDE) - label effective 2025-11-13Regulatory document · 2025 · Not rated · Population unclear · Null · Not peer reviewed · Unreviewed automatic assessment
• Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trialRandomized trial · 2025 · Study tier 2 · Different population · Benefit · Industry funded
• Effects of semaglutide in obesity-related heart failure with preserved ejection fraction across the age spectrum: Findings from the STEP-HFpEF programmeRandomized trial · 2025 · Study tier 2 · Different population · Benefit · Unreviewed automatic assessment
• Semaglutide and Exercise Function in Obesity-Related HFpEF: Insights From the STEP-HFpEF ProgramRandomized trial · 2025 · Study tier 1 · Different population · Benefit · Unreviewed automatic assessment
• FDA prescribing information: Liraglutide (LIRAGLUTIDE) - label effective 2025-10-16Regulatory document · 2025 · Not rated · Population unclear · Null · Not peer reviewed · Unreviewed automatic assessment
• FDA prescribing information: Byetta (EXENATIDE) - label effective 2025-09-02Regulatory document · 2025 · Not rated · Population unclear · Mixed · Not peer reviewed · Unreviewed automatic assessment
• Effect of the GLP-1 receptor agonist exenatide on pro-inflammatory and metabolic biomarkers in individuals with alcohol use disorder: Post hoc results from a randomized, double-blinded, placebo-controlled clinical trialRandomized trial · 2025 · Study tier 3 · Partial match · Unclear · Unreviewed automatic assessment
• Impact of Body Mass Index, Central Adiposity, and Weight Loss on the Benefits of Tirzepatide in HFpEF: The SUMMIT TrialRandomized trial · 2025 · Study tier 2 · Different population · Benefit · Unreviewed automatic assessment
• Effects of combined metformin and semaglutide therapy on body weight, metabolic parameters, and reproductive outcomes in overweight/obese women with polycystic ovary syndrome: a prospective, randomized, controlled, open-label clinical trialRandomized trial · 2025 · Study tier 3 · Different population · Benefit · Unreviewed automatic assessment
• Liraglutide improves peripheral perfusion and markers of angiogenesis and inflammation in people with type 2 diabetes and peripheral artery disease: An 18-month follow-up of a randomized clinical trialRandomized trial · 2025 · Study tier 3 · Different population · Unclear · Unreviewed automatic assessment
• The effect of GLP-1 receptor agonists on circulating inflammatory markers in type 2 diabetes patients: A systematic review and meta-analysisMeta-analysis · 2025 · Study tier 2 · Different population · Unclear · Unreviewed automatic assessment
• Interleukin-1β in circulating mononuclear cells predicts steatotic liver disease improvement after weight loss in subjects with obesity and prediabetes or type 2 diabetesRandomized trial · 2025 · Study tier 3 · Different population · Benefit · Unreviewed automatic assessment
• Treatment with orforglipron, an oral glucagon like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetesRandomized trial · 2025 · Study tier 2 · Different population · Unclear · Unreviewed automatic assessment
• Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated SteatohepatitisRandomized trial · 2025 · Study tier 1 · Different population · Benefit · Industry funded
• Effect of Semaglutide Versus Placebo on Heart Failure With Preserved Ejection Fraction in Obese Patients: A Systematic ReviewSystematic review · 2025 · Study tier 2 · Different population · Benefit · Unreviewed automatic assessment
• Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 DiabetesRandomized trial · 2025 · Study tier 1 · Different population · Benefit · Industry funded
• GLP-1RA and SGLT2i Medications for Type 2 Diabetes and Alzheimer Disease and Related DementiasRetrospective cohort · 2025 · Study tier 3 · Different population · Benefit
• Cardioprotective Glucose-Lowering Agents and Dementia Risk: A Systematic Review and Meta-AnalysisMeta-analysis · 2025 · Study tier 3 · Different population · Benefit
• Efficacy of Semaglutide and Other GLP-1 Agonists in Patients with Heart Failure With Preserved Ejection Fraction and Obesity: A Systemic Review and Meta-AnalysisMeta-analysis · 2025 · Study tier 3 · Different population · Mixed · Unreviewed automatic assessment
• Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical TrialRandomized trial · 2025 · Study tier 3 · Partial match · Benefit
• Efficacy of GLP-1 Receptor Agonist-Based Therapies on Cardiovascular Events and Cardiometabolic Parameters in Obese Individuals Without Diabetes: A Meta-Analysis of Randomized Controlled TrialsMeta-analysis · 2025 · Study tier 2 · Different population · Unclear · Unreviewed automatic assessment
• The Effects of Semaglutide on Inflammation and Immune Activation in HIV-associated LipohypertrophyRandomized trial · 2025 · Study tier 3 · Population unclear · Unclear · Unreviewed automatic assessment
• Mapping the effectiveness and risks of GLP-1 receptor agonistsRetrospective cohort · 2025 · Study tier 3 · Different population · Mixed
• Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trialRandomized trial · 2025 · Study tier 1 · Partial match · Null
• The association between glucose-dependent insulinotropic polypeptide and/or glucagon-like peptide-1 receptor agonist prescriptions and substance-related outcomes in patients with opioid and alcohol use disorders: A real-world data analysisRetrospective cohort · 2025 · Study tier 3 · Partial match · Benefit
• Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trialRandomized trial · 2025 · Study tier 3 · Different population · Benefit · Unreviewed automatic assessment
• Tirzepatide for Heart Failure with Preserved Ejection Fraction and ObesityRandomized trial · 2025 · Study tier 2 · Different population · Benefit · Industry funded
• FDA prescribing information: Liraglutide (LIRAGLUTIDE) - label effective 2025-01-30Regulatory document · 2025 · Not rated · Population unclear · Null · Not peer reviewed · Unreviewed automatic assessment
• Effects of Semaglutide Treatment on Psoriatic Lesions in Obese Patients with Type 2 Diabetes Mellitus: An Open-Label, Randomized Clinical TrialRandomized trial · 2025 · Study tier 3 · Different population · Benefit · Unreviewed automatic assessment
• Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trialsMeta-analysis · 2025 · Study tier 1 · Different population · Benefit
• Inflammatory biomarker response to GLP-1 receptor agonists versus other glucose-lowering medications in patients with type 2 diabetes: a systematic review and meta-analysisMeta-analysis · 2025 · Study tier 2 · Different population · Benefit · Unreviewed automatic assessment
• Efficacy and safety of GLP-1 receptor agonists in the treatment of obese patients with chronic heart failure: a meta-analysisMeta-analysis · 2025 · Study tier 3 · Different population · Unclear · Unreviewed automatic assessment
• Safety and efficacy of glucagon-like peptide-1 receptor agonists in patients with obstructive sleep apnea: a systematic review and meta-analysis of randomized controlled trialsMeta-analysis · 2025 · Study tier 2 · Population unclear · Mixed · Unreviewed automatic assessment
• Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the USRetrospective cohort · 2024 · Study tier 4 · Different population · Benefit
• Multisociety clinical practice guidance for the safe use of glucagon-like peptide-1 receptor agonists in the perioperative periodGuideline · 2024 · Not rated · Population unclear · Unclear
• GLP-1 Receptor Agonist Use and Risk of Suicide DeathRetrospective cohort · 2024 · Study tier 3 · Different population · Null
• Muscle matters: the effects of medically induced weight loss on skeletal muscleNarrative review · 2024 · Not rated · Population unclear · Unclear
• Once-Weekly Semaglutide in Persons with Obesity and Knee OsteoarthritisRandomized trial · 2024 · Study tier 2 · Different population · Benefit · Industry funded
• Atrial Fibrillation and Semaglutide Effects in Obesity-Related Heart Failure With Preserved Ejection Fraction: STEP-HFpEF ProgramRandomized trial · 2024 · Study tier 1 · Different population · Benefit · Unreviewed automatic assessment
• Inflammation in Obesity-Related HFpEF: The STEP-HFpEF ProgramRandomized trial · 2024 · Study tier 1 · Different population · Benefit · Unreviewed automatic assessment
• Tirzepatide for the Treatment of Obstructive Sleep Apnea and ObesityTwo phase 3, double-blind, randomized, controlled trials under one master protocol; parallel-arm, placebo-controlled, 52-week treatment duration; trial 1 (gpi1, not on pap) and trial 2 (gpi2, on pap). · 2024 · Study tier 2 · Different population · Benefit
• Inflammatory proteins associated with Alzheimer's disease reduced by a GLP1 receptor agonist: a post hoc analysis of the EXSCEL randomized placebo controlled trialRandomized trial · 2024 · Study tier 2 · Different population · Unclear · Unreviewed automatic assessment
• Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategiesNarrative review · 2024 · Not rated · Population unclear · Mixed
• Efficacy of Semaglutide by Sex in Obesity-Related Heart Failure With Preserved Ejection Fraction: STEP-HFpEF TrialsRandomized trial · 2024 · Study tier 1 · Different population · Benefit · Unreviewed automatic assessment
• Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trialRandomized trial · 2024 · Study tier 2 · Different population · Benefit · Industry funded
• Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed SemaglutideRetrospective cohort · 2024 · Study tier 4 · Different population · Harm direction
• Semaglutide and NYHA Functional Class in Obesity-Related Heart Failure With Preserved Ejection Fraction: The STEP-HFpEF ProgramRandomized trial · 2024 · Study tier 1 · Different population · Benefit · Unreviewed automatic assessment
• Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 DiabetesRandomized trial · 2024 · Study tier 1 · Different population · Benefit · Industry funded
• Is Weight Loss-Induced Muscle Mass Loss Clinically Relevant?Editorial · 2024 · Not rated · Population unclear · Unclear
• Glucagon-Like Peptide 1 Receptor Agonists and 13 Obesity-Associated Cancers in Patients With Type 2 DiabetesRetrospective cohort · 2024 · Study tier 4 · Different population · Benefit
• Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trialRandomized trial · 2024 · Study tier 2 · Different population · Benefit · Industry funded
• FDG-PET/CT-based respiration-gated lung segmentation and quantification of lung inflammation in COPD patientsRandomized trial · 2024 · Study tier 3 · Population unclear · Null · Unreviewed automatic assessment
• Bone Health After Exercise Alone, GLP-1 Receptor Agonist Treatment, or Combination Treatment: A Secondary Analysis of a Randomized Clinical TrialRandomized trial · 2024 · Study tier 2 · Different population · Harm direction · Partly industry funded
• Effects of GLP-1 receptor agonists on the degree of liver fibrosis and CRP in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: A systematic review and meta-analysisMeta-analysis · 2024 · Study tier 2 · Population unclear · Unclear · Unreviewed automatic assessment
• Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trialsRandomized trial · 2024 · Study tier 3 · Different population · Benefit · Partly industry funded · Unreviewed automatic assessment
• FDA prescribing information: WEGOVY (SEMAGLUTIDE) - label effective 2024-04-23Regulatory document · 2024 · Not rated · Population unclear · Null · Not peer reviewed · Unreviewed automatic assessment
• Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 DiabetesRandomized trial · 2024 · Study tier 2 · Different population · Unclear · Industry funded · Unreviewed automatic assessment
• Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort studyRetrospective cohort · 2024 · Study tier 3 · Different population · Null · Partly industry funded
• Trial of Lixisenatide in Early Parkinson's DiseaseRandomized trial · 2024 · Study tier 3 · Partial match · Benefit
• Liraglutide for Lower Limb Perfusion in People With Type 2 Diabetes and Peripheral Artery Disease: The STARDUST Randomized Clinical TrialRandomized trial · 2024 · Study tier 3 · Different population · Unclear · Unreviewed automatic assessment
• Continuous Positive Airway Pressure but Not GLP1-mediated Weight Loss Improves Early Cardiovascular Disease in Obstructive Sleep Apnea: A Randomized Proof-of-Concept StudyRandomized trial · 2024 · Study tier 3 · Different population · Benefit · Unreviewed automatic assessment
• Efficacy and safety of semaglutide 2.4 mg for weight loss in overweight or obese adults without diabetes: An updated systematic review and meta-analysis including the 2-year STEP 5 trialMeta-analysis · 2024 · Study tier 2 · Different population · Unclear · Unreviewed automatic assessment
• Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients With Heart Failure With Preserved Ejection Fraction and Obesity: A Prespecified Analysis of the STEP-HFpEF TrialRandomized trial · 2024 · Study tier 2 · Different population · Benefit · Unreviewed automatic assessment
• Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical TrialRandomized trial · 2024 · Study tier 1 · Different population · Benefit · Industry funded
• Association of semaglutide with risk of suicidal ideation in a real-world cohortRetrospective cohort · 2024 · Study tier 3 · Different population · Null
• Effects and plasma proteomic analysis of GLP-1RA versus CPA/EE, in combination with metformin, on overweight PCOS women: a randomized controlled trialRandomized trial · 2024 · Study tier 3 · Different population · Benefit · Unreviewed automatic assessment
• Oral Adverse Effects of Semaglutide Therapy: A Narrative ReviewPharmacovigilance · 2024 · Study tier 4 · Different population · Harm direction · Unreviewed automatic assessment
• Anti-inflammatory effect of semaglutide: updated systematic review and meta-analysisMeta-analysis · 2024 · Study tier 2 · Different population · Unclear · Unreviewed automatic assessment
• Semaglutide and Cardiovascular Outcomes in Obesity without DiabetesRandomized trial · 2023 · Study tier 1 · Different population · Benefit · Industry funded
• FDA prescribing information: Trulicity (DULAGLUTIDE) - label effective 2023-12-12Regulatory document · 2023 · Not rated · Population unclear · Null · Not peer reviewed · Unreviewed automatic assessment
• FDA prescribing information: Trulicity (DULAGLUTIDE) - label effective 2023-12-09Regulatory document · 2023 · Not rated · Population unclear · Null · Not peer reviewed · Unreviewed automatic assessment
• Results from three phase 1 trials of NNC9204-1177, a glucagon/GLP-1 receptor co-agonist: Effects on weight loss and safety in adults with overweight or obesityRandomized trial · 2023 · Study tier 3 · Different population · Unclear · Unreviewed automatic assessment
• Semaglutide in Patients With Obesity and Heart Failure Across Mildly Reduced or Preserved Ejection FractionDesign unknown · 2023 · Not rated · Population unclear · Benefit · Unreviewed automatic assessment
• FDA prescribing information: Ozempic (SEMAGLUTIDE) - label effective 2023-11-22Regulatory document · 2023 · Not rated · Population unclear · Null · Not peer reviewed · Unreviewed automatic assessment
• FDA prescribing information: OZEMPIC (SEMAGLUTIDE) - label effective 2023-11-17Regulatory document · 2023 · Not rated · Population unclear · Null · Not peer reviewed · Unreviewed automatic assessment
• Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight LossRetrospective cohort · 2023 · Study tier 3 · Different population · Harm direction
• Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and ObesityRandomized, double-blind, placebo-controlled, parallel-group, multicentre, phase 3 trial; 52-week treatment period · 2023 · Study tier 2 · Different population · Benefit
• Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 TrialRandomized trial · 2023 · Study tier 2 · Different population · Mixed · Industry funded
• FDA prescribing information: TRULICITY (DULAGLUTIDE) - label effective 2023-08-05Regulatory document · 2023 · Not rated · Population unclear · Null · Not peer reviewed · Unreviewed automatic assessment
• Effect of liraglutide on atherosclerosis in patients with impaired glucose tolerance: A double‑blind, randomized controlled clinical trialRandomized trial · 2023 · Study tier 3 · Different population · Unclear · Unreviewed automatic assessment
• FDA prescribing information: TRULICITY (DULAGLUTIDE) - label effective 2023-05-03Regulatory document · 2023 · Not rated · Population unclear · Null · Not peer reviewed · Unreviewed automatic assessment
• Biomarker Changes Associated With Both Dulaglutide and Cardiovascular Events in the REWIND Randomized Controlled Trial: A Nested Case-Control Post Hoc AnalysisRandomized trial · 2023 · Study tier 2 · Population unclear · Unclear · Unreviewed automatic assessment
• Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trialRandomized trial · 2023 · Study tier 3 · Different population · Unclear · Unreviewed automatic assessment
• GLP-1 Receptor Agonists and the Risk of Thyroid CancerCase-control · 2023 · Study tier 4 · Different population · Harm direction
• Comparative effects of weight loss and incretin-based therapies on vascular endothelial function, fibrinolysis and inflammation in individuals with obesity and prediabetes: A randomized controlled trialRandomized, parallel-group, quadruple-blind (drug arms), placebo-controlled trial; 3 arms (liraglutide, hypocaloric diet, sitagliptin) in 2:1:1 ratio; 14 weeks; measurements at baseline, 2 weeks (pre-weight-loss), and 14 weeks. · 2023 · Study tier 3 · Different population · Mixed
• Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity (STEP 1, 2, and 3): Exploratory analyses of three randomised, double-blind, placebo-controlled, phase 3 trialsRandomized trial · 2023 · Study tier 3 · Different population · Unclear · Industry funded · Unreviewed automatic assessment
• Effects of dulaglutide on endothelial progenitor cells and arterial elasticity in patients with type 2 diabetes mellitusCell / in-vitro · 2022 · Study tier 4 · Not human evidence · Unclear · Unreviewed automatic assessment
• Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trialsRandomized trial · 2022 · Study tier 1 · Different population · Unclear · Unreviewed automatic assessment
• Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extensionRandomized trial · 2022 · Study tier 2 · Different population · Harm direction · Industry funded
• Proinflammatory biomarkers are associated with prediabetes in patients with schizophreniaRandomized trial · 2022 · Study tier 3 · Different population · Null · Unreviewed automatic assessment
• Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical TrialsMeta-analysis · 2022 · Study tier 1 · Different population · Harm direction
• Glucagon-like peptide-1 receptor agonist liraglutide therapy for psoriasis patients with type 2 diabetes: a randomized-controlled trialRandomized trial · 2022 · Study tier 3 · Different population · Benefit · Unreviewed automatic assessment
• Efficacy of liraglutide in patients with diabetic nephropathy: a meta-analysis of randomized controlled trialsMeta-analysis · 2022 · Study tier 2 · Population unclear · Unclear · Unreviewed automatic assessment
• The dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: A post hoc analysisClinical trial · 2022 · Study tier 4 · Different population · Null · Unreviewed automatic assessment
• Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: A systematic review and meta-analysis of randomized controlled trialsMeta-analysis · 2022 · Study tier 2 · Different population · Harm direction · Unreviewed automatic assessment
• Short-term combined treatment with exenatide and metformin for overweight/obese women with polycystic ovary syndromeRandomized trial · 2021 · Study tier 3 · Different population · Unclear · Unreviewed automatic assessment
• Effects of exenatide on urinary albumin in overweight/obese patients with T2DM: a randomized clinical trialRandomized trial · 2021 · Study tier 3 · Different population · Benefit · Unreviewed automatic assessment
• Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trialsMeta-analysis · 2021 · Study tier 1 · Different population · Benefit
• Effect of liraglutide on expression of inflammatory genes in type 2 diabetesRandomized trial · 2021 · Study tier 3 · Different population · Mixed · Unreviewed automatic assessment
• Glucagon-like peptide-1 receptor agonists improve biomarkers of inflammation and oxidative stress: A systematic review and meta-analysis of randomised controlled trialsMeta-analysis · 2021 · Study tier 2 · Different population · Benefit · Unreviewed automatic assessment
• Effects of liraglutide versus sitagliptin on circulating cardiovascular biomarkers, including circulating progenitor cells, in individuals with type 2 diabetes and obesity: Analyses from the LYDIA trialDesign unknown · 2021 · Not rated · Population unclear · Unclear · Unreviewed automatic assessment
• Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both CombinedRandomized trial · 2021 · Study tier 2 · Different population · Benefit · Partly industry funded
• Once-Weekly Semaglutide in Adults with Overweight or ObesityRandomized trial · 2021 · Study tier 1 · Different population · Benefit · Industry funded
• Effects of Incretin-based Therapy on High-sensitivity C-reactive Protein in Patients with Type 2 Diabetes: A Systematic Review and Meta-AnalysisMeta-analysis · 2020 · Study tier 2 · Different population · Unclear · Unreviewed automatic assessment
• Effect of short-acting exenatide administered three times daily on markers of cardiovascular disease in type 1 diabetes: A randomized double-blind placebo-controlled trialRandomized trial · 2020 · Study tier 3 · Population unclear · Unclear · Industry funded · Unreviewed automatic assessment
• Efficacy of liraglutide intervention in myocardial infarction : A meta-analysis of randomized controlled trialsMeta-analysis · 2020 · Study tier 2 · Population unclear · Mixed · Unreviewed automatic assessment
• Comparison of the effects of twice-daily exenatide and insulin on carotid intima-media thickness in type 2 diabetes mellitus patients: a 52-week randomized, open-label, controlled trialRandomized trial · 2020 · Study tier 3 · Different population · Unclear · Unreviewed automatic assessment
• Liraglutide treatment reduced interleukin-6 in adults with type 1 diabetes but did not improve established autonomic or polyneuropathyRandomized trial · 2019 · Study tier 3 · Population unclear · Unclear · Unreviewed automatic assessment
• Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: A randomized trialCrossover trial · 2019 · Study tier 3 · Different population · Unclear · Unreviewed automatic assessment
• Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trialRandomized trial · 2019 · Study tier 1 · Different population · Benefit · Industry funded
• Meta-analysis of the efficacy of liraglutide in patients with type 2 diabetes accompanied by incipient nephropathyMeta-analysis · 2019 · Study tier 2 · Different population · Harm direction · Unreviewed automatic assessment
• Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesityDesign unknown · 2019 · Not rated · Population unclear · Unclear · Partly industry funded · Unreviewed automatic assessment
• The Effects of Once-Weekly Dulaglutide and Insulin Glargine on Glucose Fluctuation in Poorly Oral-Antidiabetic Controlled Patients with Type 2 Diabetes MellitusRandomized trial · 2019 · Study tier 3 · Different population · Unclear · Unreviewed automatic assessment
• A Randomized Study to Compare the Effects of Once-Weekly Dulaglutide Injection and Once-Daily Glimepiride on Glucose Fluctuation of Type 2 Diabetes Mellitus Patients: A 26-Week Follow-UpRandomized trial · 2019 · Study tier 3 · Different population · Unclear · Unreviewed automatic assessment
• Thromboxane-Dependent Platelet Activation in Obese Subjects with Prediabetes or Early Type 2 Diabetes: Effects of Liraglutide- or Lifestyle Changes-Induced Weight LossRandomized trial · 2018 · Study tier 3 · Different population · Benefit · Unreviewed automatic assessment
• Treatment with GLP1 receptor agonists reduce serum CRP concentrations in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trialsMeta-analysis · 2017 · Study tier 2 · Different population · Unclear · Unreviewed automatic assessment
• Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: A sub-analysis of a randomized, placebo-controlled, double-blind, crossover trialCrossover trial · 2017 · Study tier 3 · Different population · Benefit · Unreviewed automatic assessment
• Reduction of visceral fat by liraglutide is associated with ameliorations of hepatic steatosis, albuminuria, and micro-inflammation in type 2 diabetic patients with insulin treatment: a randomized control trialRandomized trial · 2017 · Study tier 3 · Different population · Mixed · Unreviewed automatic assessment
• GLP-1 analogue-induced weight loss does not improve obesity-induced AT dysfunctionRandomized trial · 2017 · Study tier 3 · Different population · Null · Unreviewed automatic assessment
• Comparison of exenatide and acarbose on intra-abdominal fat content in patients with obesity and type-2 diabetes: A randomized controlled trialRandomized trial · 2017 · Study tier 3 · Different population · Unclear · Unreviewed automatic assessment
• Semaglutide and Cardiovascular Outcomes in Patients with Type 2 DiabetesRandomized trial · 2016 · Study tier 2 · Different population · Mixed · Industry funded
• Liraglutide and Cardiovascular Outcomes in Type 2 DiabetesRandomized trial · 2016 · Study tier 1 · Different population · Benefit · Partly industry funded
• Benefits and Harms of Once-Weekly Glucagon-like Peptide-1 Receptor Agonist Treatments: A Systematic Review and Network Meta-analysisMeta-analysis · 2016 · Study tier 2 · Different population · Unclear · Unreviewed automatic assessment
• Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide studyRandomized trial · 2015 · Study tier 2 · Different population · Benefit · Unreviewed automatic assessment
• Evaluation of exenatide versus insulin glargine for the impact on endothelial functions and cardiovascular risk markersRandomized trial · 2014 · Study tier 3 · Different population · Benefit · Unreviewed automatic assessment
• Effects of exenatide, insulin, and pioglitazone on liver fat content and body fat distributions in drug-naive subjects with type 2 diabetesRandomized trial · 2014 · Study tier 3 · Different population · Unclear · Unreviewed automatic assessment
• Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver diseaseRandomized trial · 2013 · Study tier 3 · Different population · Unclear · Unreviewed automatic assessment
• Benefits of liraglutide treatment in overweight and obese older individuals with prediabetesRandomized trial · 2013 · Study tier 3 · Different population · Benefit · Unreviewed automatic assessment
• Effect of laparoscopic Roux-en-Y gastric bypass surgery on type 2 diabetes mellitus with hypertension: a randomized controlled trialRandomized trial · 2013 · Study tier 3 · Different population · Benefit · Unreviewed automatic assessment
• Exenatide plus metformin compared with metformin alone on β-cell function in patients with Type 2 diabetesRandomized trial · 2012 · Study tier 3 · Different population · Unclear · Unreviewed automatic assessment
• Addition of liraglutide in patients with Type 2 diabetes well controlled on metformin monotherapy improves several markers of vascular functionRandomized trial · 2012 · Study tier 3 · Different population · Unclear · Unreviewed automatic assessment
• Effects of exenatide vs. metformin on endothelial function in obese patients with pre-diabetes: a randomized trialRandomized trial · 2012 · Study tier 3 · Different population · Unclear · Unreviewed automatic assessment
• Exenatide exerts a potent antiinflammatory effectRandomized trial · 2012 · Study tier 3 · Population unclear · Unclear · Unreviewed automatic assessment
• Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patientsRandomized trial · 2011 · Study tier 3 · Population unclear · Benefit · Unreviewed automatic assessment
• Effect of exenatide on inflammatory and oxidative stress markers in patients with type 2 diabetes mellitusRandomized trial · 2011 · Study tier 3 · Different population · Benefit · Unreviewed automatic assessment
• Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body compositionRandomized trial · 2010 · Study tier 3 · Different population · Benefit · Unreviewed automatic assessment
• Exenatide versus glibenclamide in patients with diabetesRandomized trial · 2010 · Study tier 3 · Population unclear · Benefit · Unreviewed automatic assessment